ประสิทธิผลของยา Sofosbuvir/Velpatasvir ร่วมกับและไม่ร่วมกับ Ribavirin ในการรักษา ผู้ป่วยไวรัสตับอักเสบซี ณ โรงพยาบาลอุดรธานี

Nitipon Simasingha

Authors

Nitipon Simasingha Udon Thani Hospital

Keywords:

Hepatitis C, Hepatitis C drug, Effectiveness

Abstract

Hepatitis C virus (HCV) is a primary cause of liver cirrhosis and hepatocellular carcinoma (HCC). Treatment with sofosbuvir/velpatasvir is associated with reduced mortality rates, decreased incidence of liver failure, and a decline in liver-related complications, including HCC. The objective of this study was to evaluated the effectiveness of sofosbuvir/velpatasvir with or without ribavirin for chronic hepatitis C treatment at the hepatitis clinic, Udon Thani hospital. This study was a retrospective descriptive study. Data were collected from HCV patients aged 18–70 years at the hepatitis clinic of Udon Thani hospital between December 7, 2024, and December 31, 2025. A total of 100 patients were enrolled and divided into two groups: those receiving sofosbuvir/velpatasvir (n = 50) and those receiving sofosbuvir/velpatasvir + ribavirin (n = 50). Statistical analyses included descriptive statistics, Fisher's exact test, and Mann-Whitney U test. Treatment effectiveness was measured by the sustained virological response at 12 weeks post-treatment (SVR12). The study included 100 patients with mean age of 54.26±12.77 years. Of these, 55 patients were male (55.00 %), 37 patients had cirrhosis (37.00%), and 22 patients were co-infected with HIV (22.00%). All patients were treatment-naïve. The overall SVR12 rate were cure 97 from 100 patients (97.00%). Sofosbuvir/velpatasvir group from 49 patients were achieved SVR12 (98.00%). Sofosbuvir/velpatasvir + ribavirin group from 48 patients were achieved SVR12 (96.00%). The SVR12 rate was 90.90% (20/22) in patients with HIV co-infection and 94.59% (35/37) in patients with cirrhosis. There was no statistically significant difference in the SVR12 rate between the cirrhotic and non-cirrhotic groups (p-value = 0.315). Furthermore, among the cured group, the Fibrosis-4 (FIB-4) index decreased, although this reduction was not statistically significant. Adverse event, minor anemia and fatigue were observed in the ribavirin group; however, 100.00% of patients were able to complete the full course of treatment. Therefore, both regimens sofosbuvir/velpatasvir alone and in combination with ribavirin demonstrated high effectiveness (98.00% and 96.00%, respectively) and demonstrates a strong safety profile for all subgroups of HCV patients within the real-world clinical context of Udon Thani hospital that suitable and correlation with Thai public health policy “Test and Treat HCV elemination 2030”

References

Jacinta AH, Raymond TC. Hepatitis C. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 11th ed. Philadelphia: Saunders-Elsevier; 2020. p.1243-82.

Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of Hepatitis C virus infection: Host, viral, and environmental factors. JAMA. 2000;284(4):450-6.

D’souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–83. doi:10.3748/wjg.v26.i38.5759.

World Health Organization. Hepatitis C [fact sheet]. Geneva: World Health Organization; 2026 [cited 2026 Jul 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 [Internet]. 2021 [cited 2026 Jul 28]. Available from: https://www.who.int/publications/i/item/9789240027077

ชีวนันท์ เลิศพิริยสุวัฒน์, สุชาดา เจียมศิริ, บรรณาธิการ. ยุทธศาสตร์กำจัดโรคไวรัสตับอักเสบ พ.ศ. 2565–2573. นนทบุรี: กรมควบคุมโรค กระทรวงสาธารณสุข; 2566.

Van Der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi:10.1001/jama.2012.144878

Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS.2015; 10(5):309-15. doi:10.1097/COH.0000000000000175

Re Lo V. Extrahepatic complications of hepatitis C virus infection in HIV and the impact of successful antiviral treatment. Clinical Infectious Diseases. 2017;64(4):498-500. doi:10.1093/cid/ciw814

Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology. 2015;149:1345–60. doi:10.1053/j.gastro.2015.08.035

Cheng X, Ghany M G. Key Milestones in HCV Discovery and Therapeutics. Innovation. 2020;1(3): 100067. doi:10.1016/j.xinn.2020.100067

Bhattacharya D, Aronsohn A, Price J, Lo Re V, Heald J, Demisashi G, et al. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. 2023;1-18. doi:10.1093/cid/ciad319

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. New England Journal of Medicine. 2014;370(20):1889–98. doi:10.1056/nejmoa1402454

Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, et al. Resistance to hepatitis C virus: Potential genetic and immunological determinants. The Lancet Infectious. 2015;15(4):451-60. doi:10.1016/S1473-3099(14)70965-X

Ahmed H, Abushouk AI, Attia A, Gadelkarim M, Gabr M, Negida A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis. Journal of Infection and Public Health. 2018;11:156–64. doi:10.1016/j.jiph.2017.09.004

Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection. Ann Intern Med. 2015;163(11):818–26. doi:10.7326/M15-1000

Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection. Ann Intern Med. 2015;163(11):809–17. doi:10.7326/M15-1014

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New England Journal of Medicine. 2015;373(27):2599-607. doi:10.1056/nejmoa1512610

Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine. 2015;373(27):2618–28. doi:10.1056/nejmoa1512614

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47(9):1288–95. doi:10.1111/apt.14592

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine. 2015;373(27):2608–17. doi:10.1056/nejmoa1512612

Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 2019;4(2): 127-34. doi:10.1016/S2468 1253(18)30343-1

Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. Drugs 2016;76(16):1567-78. doi:10.1007/s40265-016-0648-2

Weisberg IS, Jacobson IM. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. Expert Opin Pharmacother. 2017;18(5):535-43. doi:10.1080/14656566.2017.1282459

Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, et al. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: A multicentre cohort study. BMC Gastroenterol. 2020;20(1):1-15. doi:10.1186/s12876-020-01196-0

พรพยอม นุ่มประพฤติ. ประสิทธิผลของยา Sofosbuvir-Velpatasvir ในการรักษาผู้ป่วยโรคไวรัสตับอักเสบซีของโรงพยาบาลวชิระภูเก็ต. มหาราชนครศรีธรรมราชเวชสาร. 2567;8(1):149-61.

Ngamjarus C, Pattanittum P. n4Studies: application for sample size calculation in health science research. Version 2.3. App store; 2024.

โชติพงษ์ ศิริพิพัฒนมงคล. ประสิทธิผลและคามปลอดภัยของการรักษาผู้ป่วยโรคไรัตับอักเสบซีเรื้อรังด้วยยาเพ็คกิเลตเต็ดอินเตอร์ฟิรอนและไรบาไวรินและยารักษาไรัตับอักเสบซีชนิดใหม่ (direct acting antiviral: DAA) ในโรงพยาบาลเชียงรายประชานุเคราะห์. เชียงรายเวชสาร. 2562;11(1):41-54.